Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
4.02M | 7.30M | 6.07M | 5.17M | 12.63M | 7.91M | Gross Profit |
-11.46M | -8.22M | 4.53M | -10.21M | 12.63M | -4.93M | EBIT |
-21.75M | -14.74M | -18.95M | -20.17M | -573.00K | -20.69M | EBITDA |
-17.02M | -13.27M | -17.40M | -15.35M | -9.86M | -13.24M | Net Income Common Stockholders |
-21.78M | -14.12M | -18.73M | -22.50M | -28.52M | -20.39M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
2.56M | 19.17M | 35.63M | 53.84M | 31.66M | 23.44M | Total Assets |
14.72M | 33.96M | 40.95M | 58.82M | 38.17M | 36.10M | Total Debt |
0.00 | 8.76M | 857.00K | 2.29M | 1.74M | 675.00K | Net Debt |
-2.56M | -10.42M | -34.77M | -51.55M | -29.91M | -22.77M | Total Liabilities |
2.88M | 15.96M | 9.84M | 11.37M | 15.03M | 25.08M | Stockholders Equity |
11.84M | 18.00M | 31.11M | 47.45M | 23.14M | 11.02M |
Cash Flow | Free Cash Flow | ||||
-18.62M | -16.66M | -19.44M | -19.87M | -12.76M | 3.17M | Operating Cash Flow |
-18.41M | -15.98M | -19.36M | -19.73M | -12.48M | 3.23M | Investing Cash Flow |
-203.00K | -676.00K | -86.00K | -144.00K | -281.00K | -58.00K | Financing Cash Flow |
6.04M | 53.00K | 1.23M | 43.48M | 20.98M | 17.70M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $1.10B | 83.22 | 3.42% | ― | 14.88% | -86.70% | |
64 Neutral | $125.40B | ― | -3.15% | ― | 11.64% | -114.72% | |
60 Neutral | $1.34B | ― | -23.01% | ― | 168.06% | 44.66% | |
56 Neutral | $26.99M | ― | -62.70% | ― | 47.05% | 40.66% | |
53 Neutral | $421.09M | ― | 91.25% | ― | -12.26% | 32.86% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
46 Neutral | $249.73M | ― | -33.88% | ― | ― | -22.66% |
Pulmatrix and Cullgen have announced a merger to form a Nasdaq-listed entity focused on targeted protein degradation, with promising clinical trials in cancer and pain management underway. The merger, expected to finalize by March 2025, will see Cullgen shareholders owning the majority stake, while Pulmatrix plans to distribute a cash dividend to its shareholders. This strategic move aims to enhance growth through Cullgen’s innovative drug development platform, with the combined company holding approximately $65 million in funds to support multiple clinical milestones.